Boston Phar­ma­ceu­ti­cals hits Phase 2 goals as it tries to keep up with MASH com­peti­tors

Boston Phar­ma­ceu­ti­cals suc­ceed­ed on two close­ly watched ef­fi­ca­cy end­points for its Phase 2 MASH study, putting the com­pa­ny in con­tention with oth­er biotechs seek­ing to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER